Söndag 22 December | 02:26:17 Europe / Stockholm

Prenumeration

Kalender

Tid*
2025-11-12 07:00 Kvartalsrapport 2025-Q3
2025-08-21 07:00 Kvartalsrapport 2025-Q2
2025-05-15 07:00 Kvartalsrapport 2025-Q1
2025-02-20 08:00 Bokslutskommuniké 2024
2024-11-13 - Kvartalsrapport 2024-Q3
2024-10-01 - Split LIFE 13:1
2024-08-27 - Kvartalsrapport 2024-Q2
2024-05-16 - Extra Bolagsstämma 2024
2024-05-08 - Kvartalsrapport 2024-Q1
2024-05-02 - X-dag ordinarie utdelning LIFE 0.00 NOK
2024-04-30 - Årsstämma
2024-02-27 - Bokslutskommuniké 2023
2023-11-14 - Kvartalsrapport 2023-Q3
2023-08-23 - Kvartalsrapport 2023-Q2
2023-05-11 - Kvartalsrapport 2023-Q1
2023-05-08 - X-dag ordinarie utdelning LIFE 0.00 NOK
2023-04-18 - Årsstämma
2023-02-28 - Bokslutskommuniké 2022
2022-08-25 - Kvartalsrapport 2022-Q2
2022-05-09 - X-dag ordinarie utdelning LIFE 0.00 NOK
2022-05-06 - Årsstämma
2022-04-21 - Bokslutskommuniké 2021
2021-09-30 - Extra Bolagsstämma 2021
2021-08-05 - Kvartalsrapport 2021-Q2
2021-05-10 - X-dag ordinarie utdelning LIFE 0.00 NOK
2021-05-07 - Årsstämma
2021-04-20 - Bokslutskommuniké 2020
2020-06-26 - Årsstämma
2020-06-01 - Bokslutskommuniké 2019
2019-02-07 - Split LIFE 4:1
2018-12-11 - Extra Bolagsstämma 2018

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriMedicinteknik
Lifecare är ett norskt bolag verksamma inom medicinteknik. Idag är bolaget specialiserade inom forskning och utveckling av diabetes. Produkterna är patenterade och används som glukosgivare. Mikrosensorerna injiceras under huden på patientens handled, och fungerar vidare som en realtidsuppdatering av glukosnivån i patienten. Utöver bidrar tekniken med larmsensor samt tillgång till historisk data över patientens glukosnivå. Bolaget etablerades under 2006 och har sitt huvudkontor i Bergen, Norge.
2024-10-15 23:05:03
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR
INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER
JURISDICTION WHERE SUCH PUBLICATION, DISTRIBUTION OR RELEASE WOULD BE
UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

Reference is made to the stock exchange announcement made by Lifecare ASA (the
"Company") on 8 October 2024 announcing the launch of the retail offering (the
"Offering") of up to 1,000,000 new shares (the "Offer Shares") to the public
in Norway, Sweden and Denmark.

The Company is pleased to announce that the Offering has been successfully
placed, raising gross proceeds of NOK 16,625,320 through the allocation of
831,266 Offer Shares at the offer price of NOK 20 per share.

All applicants who submitted a valid application have received full
allocation. All applicants have been treated equally in the allocation. No
allocation has been given below NOK 10,500, and the Company has set a maximum
allocation of NOK 2,000,000.

Notifications of allocated Offer Shares and the corresponding amount to be
paid by investors are expected to be communicated to investors on or about 16
October 2024. Investors who have access to investor services through their VPS
account manager should be able to see how many Offer Shares they have been
allocated from on or about 12:00 (CEST) on 16 October 2024.

Payment for allocated Offer Shares falls due on or about 18 October 2024. The
Offer Shares are expected to be pre-paid by the Manager (as defined below)
pursuant to a pre-payment agreement between the Company and the Manager, in
order to facilitate prompt registration of the share capital increase
pertaining to the issuance of Offer Shares, and the share capital increase is
expected to be registered with the Norwegian Register of Business Enterprises
on or about 18 October 2024. Following registration of the share capital
increase, the Offer Shares are expected to be delivered to applicants in the
VPS on or about 22 October 2024, subject to timely payment having been
received. The Offer Shares will be tradable following delivery of the Offer
Shares to applicants in the VPS, expected on or about 22 October 2024.

The Company's shares, including the Offer Shares, are expected to become
tradable on Oslo Børs on or about 22 October 2024.

Following registration of the share capital increase pertaining to the
issuance of the Offer Shares, the Company will have a share capital of NOK
82,435,490.80 divided into 15,852,979 shares, each with a nominal value of NOK
5.20.

Advisors

Carnegie AS is acting as manager in connection with the Offering (the
"Manager"). Nordnet Bank AB ("Nordnet") is acting as placing agent in the
Offering. Advokatfirmaet Schjødt AS is acting as Norwegian legal counsel to
the Company.

About Lifecare:

Lifecare is a clinical stage medical sensor company developing technology for
sensing and monitoring of various body analytes. Lifecare's main focus is to
bring the next generation of Continuous Glucose Monitoring ("CGM") systems to
market. Lifecare enables osmotic pressure as sensing principle, combined with
the ability to manipulate Nano-granular Tunnelling Resistive sensors ("NTR")
on the sensor body for read-out of pressure variations. Lifecare's sensor
technology is referred to as "Sencell" and is suitable for identifying and
monitoring the occurrence of a wide range of analytes and molecules in the
human body and in pets.

Contacts
For further information, please contact:

* Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40
* Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

Important information

This announcement is not an offer to sell or a solicitation of any offer to
buy any securities of the Company. The information contained in this
announcement is for information purposes only and does not purport to be full
or complete. No reliance may be placed by any person for any purpose on the
information contained in this announcement or its accuracy, fairness or
completeness.

Copies of this announcement are not being made and may not be distributed or
sent into any other jurisdiction than Norway, Sweden and Denmark, including
but not limited to the United States of America, Australia, Canada.

Any offering of the securities referred to in this announcement is made by
means of the prospectus prepared by the Company in connection with the
Offering and the listing of the Company's shares on Oslo Børs, alternatively
Euronext Expand (the "Prospectus"). This announcement is not a prospectus for
the purposes of Regulation (EU) 2017/1129 of the European Parliament and of
the Council of 14 June 2017 on the prospectus to be published when securities
are offered to the public or admitted to trading on a regulated market, and
repealing Directive 2003/71/EC (together with any related implementing and
delegated regulations, the "Prospectus Regulation"). Investors should not
invest in any securities referred to in this announcement except on the basis
of information contained in the aforementioned Prospectus.

The securities referred to in this announcement have not been and will not be
registered under the U.S. Securities Act of 1933, as amended (the "Securities
Act"), and accordingly may not be offered or sold in the United States absent
registration or an exemption from the registration requirements of the
Securities Act and in accordance with applicable U.S. state securities laws.
The Company does not intend to register any offering in the United States or
to conduct a public offering of securities in the United States.

Copies of this announcement are not being, and should not be, distributed in
or sent into the United States (including its territories and possessions, any
State of the United States and the District of Columbia), Australia, Canada or
Japan. The securities described herein have also not been and will not be
registered under the applicable securities laws of the United States,
Australia, Canada or Japan and, subject to certain exemptions, may not be
offered or sold in or into or for the account or benefit of any person having
a registered address in, or located or resident in the United States,
Australia, Canada or Japan. There will be no public offering of the securities
described herein in the United States, Australia, Canada or Japan.

Matters discussed in this announcement may constitute forward-looking
statements. Forward-looking statements are statements that are not historical
facts and may be identified by words such as "believe," "expect,"
"anticipate", "intends", "estimate", "will", "may", "continue", "should" and
similar expressions. The forward-looking statements in this release are based
upon various assumptions, many of which are based, in turn, upon further
assumptions. Although the Company believes that these assumptions were
reasonable when made, these assumptions are inherently subject to significant
known and unknown risks, uncertainties, contingencies and other important
factors which are difficult or impossible to predict and are beyond its
control. Such risks, uncertainties, contingencies and other important factors
could cause actual events to differ materially from the expectations expressed
or implied in this release by such forward-looking statements. The
information, opinions and forward-looking statements contained in this
announcement speak only as at its date and are subject to change without
notice. Neither the Company nor the Manager undertake any obligation to
review, update, confirm or release publicly any revisions to any
forward-looking statements to reflect events that occur or circumstances that
arise in relation to the content of this communication.

The Manager is acting exclusively for the Company and no one else in
connection with the Offering. It will not regard any other person as its
clients in relation to the planned Offering and will not be responsible to
anyone other than the Company for providing the protections afforded to its
clients, nor for providing advice in relation to the offering, the contents of
this announcement or any transaction, arrangement or other matter referred to
herein.

Neither the Manager nor any of its directors, officers, employees, advisers or
agents accept any responsibility or liability whatsoever for or makes any
representation or warranty, express or implied, as to the truth, accuracy or
completeness of the information in this release (or whether any information
has been omitted from the release) or any other information relating to the
Company, whether written, oral or in a visual or electronic form, and
howsoever transmitted or made available, or for any loss howsoever arising
from any use of this release or its contents or otherwise arising in
connection therewith.

This information has been submitted pursuant to the Securities Trading Act §
5-12 and MAR Article 17. The information was submitted for publication at
2024-10-15 23:05 CEST.